Cancer-selective apoptotic effects of extracellular and intracellular Par-4

被引：68
|
作者：
Shrestha-Bhattarai, T. [2 ]
Rangnekar, V. M. [1 ,2 ,3 ,4 ]
机构：
[1] Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA
[2] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA
[3] Univ Kentucky, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40536 USA
[4] Univ Kentucky, LP Markey Canc Ctr, Lexington, KY 40536 USA
来源：
ONCOGENE | 2010年 / 29卷 / 27期
关键词：
Par-4; cell surface GRP78; apoptosis; TUMOR-SUPPRESSOR PAR-4; NECROSIS-FACTOR-ALPHA; PROTEIN PAR-4; ENDOPLASMIC-RETICULUM; PROSTATIC-CANCER; DOWN-REGULATION; ONCOGENIC RAS; CELLS; GENE; KINASE;
D O I：
10.1038/onc.2010.141
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Selectivity toward cancer cells is the most desirable element in cancer therapeutics. Par-4 is a cancer cell-selective proapoptotic protein that functions intracellularly in the cytoplasmic and nuclear compartments as a tumor suppressor. Moreover, recent findings indicate that the Par-4 protein is secreted by cells, and extracellular Par-4 induces cancer cell-specific apoptosis by interaction with the cell-surface receptor GRP78. This review describes the mechanisms underlying the apoptotic effects of both extracellular and intracellular Par-4 acting through its effector domain SAC. Oncogene (2010) 29, 3873-3880; doi:10.1038/onc.2010.141; published online 3 May 2010
引用
收藏
页码：3873 / 3880
页数：8
相关论文
共 50 条
  • [1] Cancer-selective apoptotic effects of extracellular and intracellular Par-4
    T Shrestha-Bhattarai
    V M Rangnekar
    Oncogene, 2010, 29 : 3873 - 3880
  • [2] Cancer-Selective Apoptosis by Tumor Suppressor Par-4
    Hebbar, Nikhil
    Shrestha-Bhattarai, Tripti
    Rangnekar, Vivek M.
    ANTICANCER GENES, 2014, 818 : 155 - 166
  • [3] The phosphoinositide 3-kinase/Akt1/Par-4 axis: A cancer-selective therapeutic target
    Goswami, A
    Ranganathan, P
    Rangnekar, VM
    CANCER RESEARCH, 2006, 66 (06) : 2889 - 2892
  • [4] Novel Mechanism of Apoptosis Resistance in Cancer Mediated by Extracellular PAR-4
    Burikhanov, Ravshan
    Shrestha-Bhattarai, Tripti
    Qiu, Shirley
    Shukla, Nidhi
    Hebbar, Nikhil
    Lele, Subodh M.
    Horbinski, Craig
    Rangnekar, Vivek M.
    CANCER RESEARCH, 2013, 73 (02) : 1011 - 1019
  • [5] Synthesis, Cancer-Selective Antiproliferative and Apoptotic Effects of Some (±)-Naringenin Cycloaminoethyl Derivatives
    Zaim, Omer
    Doganlar, Oguzhan
    Zreigh, Mohamed M.
    Doganlar, Zeynep Banu
    Ozcan, Hafize
    CHEMISTRY & BIODIVERSITY, 2018, 15 (07)
  • [6] Role of PAR-4 in ovarian cancer
    Meynier, Sonia
    Kramer, Marianne
    Ribaux, Pascale
    Tille, Jean-Christophe
    Delie, Florence
    Petignat, Patrick
    Cohen, Marie
    ONCOTARGET, 2015, 6 (26) : 22641 - 22652
  • [7] Par-4 as therapy for colon cancer
    Irby, Rosalyn B.
    Kline, Christina L.
    Sharma, Arun K.
    CANCER RESEARCH, 2010, 70
  • [8] Gastrin signaling and Par-4 in pancreatic cancer
    Fino, Kristin K.
    Irby, Rosalyn B.
    Smith, Jill P.
    CANCER RESEARCH, 2011, 71
  • [9] Radiosensitivity with Par-4 expression in prostate cancer
    Sheikh, MS
    CANCER BIOLOGY & THERAPY, 2002, 1 (02) : 161 - 162
  • [10] Implication of a Pro-Apoptotic Protein, Prostate Apoptosis Response-4 (Par-4) in Breast Cancer
    Ye, L.
    Mansel, R. E.
    Jiang, W. G.
    CANCER RESEARCH, 2009, 69 (24) : 874S - 875S
12345